Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nassir F. Marrouche, MD, University of Utah
ClinicalTrials.gov Identifier:
NCT01150214
First received: June 22, 2010
Last updated: September 17, 2013
Last verified: September 2013
  Purpose

This is a multi-center, observational, 1-year prospective cohort study (1 year follow-up, at 3, 6 and 12 month) with approximately 675 participants. We will conduct a thorough outcomes assessment utilizing data from Magnetic Resonance Imaging (MRI) scans, as well as pre-procedure and follow-up data. Scans will be blinded to location of participating site. MRI scans will be sequenced and analyzed as they arrive from the database.

Imaging Protocol: All patients will undergo a Delayed-Enhancement MRI (DE-MRI) within 30 days prior to the atrial fibrillation (AF) ablation procedure. The purpose of the initial MRI is to quantify the degree of atrial structural remodeling or fibrosis pre-ablation. Following ablation, DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.

Clinical Follow-up: The institution where the ablation was performed will continue post-procedural care following standard of care procedures.

Atrial arrhythmia recurrences will be catalogued up to one year post-ablation and predictors of recurrences of AF will be determined by statistical analysis. The specific mechanism and electrophysiological characteristics of atrial arrhythmia recurrence will also be analyzed.

Our hypotheses are (1) DE-MRI will reproducibly stage the progression left atrium fibrosis in AF; (2) DE-MRI will reproducibly aid in quantifying and identifying the distribution of catheter ablation-related scarring in the left atrium; and (3) the stage of left atrium fibrosis pre-ablation and the amount and location of scarring will predict success of catheter ablation therapy for AF.


Condition Intervention
Atrial Fibrillation
Procedure: DE-MRI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: DECAAF: DE-MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Relationship between extent of pre-ablation fibrosis and recurrence post-ablation [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The percentage of pre-ablation fibrosis in atrial fibrillation patients can significantly impact the incidence of recurrences post-ablation.


Secondary Outcome Measures:
  • Relationship between extent of Post-ablation scar and incidence of atrial fibrillation recurrences post-catheter ablation for AF [ Time Frame: Post-ablation scar ] [ Designated as safety issue: No ]
    The extent of lesions created by ablation may have an impact on the incidence of recurrence of AF post-ablation


Enrollment: 339
Study Start Date: July 2010
Study Completion Date: September 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
DE-MRI
All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
Procedure: DE-MRI
Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population will consist of those patients who have undergone catheter ablation for atrial fibrillation.

Criteria

Inclusion Criteria:

  • Patients who underwent an AF ablation as per recent Heart Rhythm Society (HRS) consensus document, as per the University of Utah AFIB Database (IRB_00020347)
  • Patients who have had an MRI post-ablation.
  • Age ≥18 years.

Exclusion Criteria:

  • Contraindication for DE-MRI with a full dose of Gadolinium-based contrast agent.
  • Previous left atrial ablation or surgical procedure
  • Renal failure with CrCl <60 ml/min
  • Women currently pregnant, breastfeeding, or of childbearing age not currently taking or not willing to use a reliable form of contraception
  • Mental or physical inability to take part in the study
  • Uncontrolled hypertension
  • Morbid obesity (BMI > 35), or inability to be placed in MRI due to body mass.
  • Patients who have not had a DE-MRI post-ablation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01150214

Locations
United States, Florida
Florida Heart Rhythm Institute
Tampa, Florida, United States, 33606
United States, Illinois
Loyola University Medical Center
Chicago, Illinois, United States, 60153
United States, Ohio
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19104
United States, Utah
CARMA Center, University of Utah
Salt Lake City, Utah, United States, 84132
Australia, South Australia
Royal Adelaide Hospital
Norwood, South Australia, Australia, 5067
Belgium
Universitair Ziekenhuis Ghent
Ghent, Belgium, 9000
France
Hôpital Cardiologique du Haut-Lévêque/Bordeaux
Bordeaux, France, 33604
Germany
Kerckhoff Klinik
Bad Nauheim, Germany, 61231
Coburg Klinik
Coburg, Germany, 96450
Institut für Diagnostische und Interventionelle Radiologie - koln
Cologne, Germany
Asklepios Klinik St. Georg
Hamburg, Germany, 20099
Universitatsklinikum Leipzig
Leipzig, Germany, 04103
Netherlands
St Antonius Ziekenhuis Hospital
Nieuwegein, Netherlands, 3430
Spain
Hospital Clinic de Barcelona
Barcelona, Catalonia, Spain, 08036
Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Nassir F Marrouce, MD, FHRS CARMA Center, University of Utah
  More Information

Additional Information:
Publications:
Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ; Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007 Jun;9(6):335-79. No abstract available. Erratum in: Europace. 2009 Jan;11(1):132.

Responsible Party: Nassir F. Marrouche, MD, Associate Professor, University of Utah
ClinicalTrials.gov Identifier: NCT01150214     History of Changes
Other Study ID Numbers: IRB_00039522
Study First Received: June 22, 2010
Last Updated: September 17, 2013
Health Authority: United States: Institutional Review Board
Germany: Ethics Commission
Australia: Human Research Ethics Committee
Spain: Ethics Committee
Netherlands: Medical Ethics Review Committee (METC)
France: Institutional Ethical Committee
Belgium: Ethics Committee

Keywords provided by University of Utah:
atrial fibrillation
af
magnetic resonance imaging
mri
left atrium
fibrosis
structural remodeling

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on November 25, 2014